Boston Scientific Corporation
BSXNYSEAlpha Score of 34 reflects weak overall profile with poor momentum, poor value, strong quality, poor sentiment.
Boston Scientific Shows Strong Growth Metrics Amid Elevated Valuation Multiples
Apr 15, 2026Boston Scientific Corporation continues to demonstrate significant operational expansion, underscored by a robust 19.9% year-over-year revenue growth and a notable 55.6% increase in EPS. These figures highlight the company's strong market position within the healthcare sector, supported by a solid net margin of 14.4%. Despite this performance, the stock trades at a P/E ratio of 40.14, reflecting a premium valuation relative to its earnings. The current price sits near the upper end of its 52-week range of $61.28 to $108.14, indicating sustained investor interest over the past year. From an analytical perspective, the Alpha Score of 34.7 reveals a divergence across key metrics. While the quality sub-score remains high at 71.3, suggesting stable underlying fundamentals, the momentum sub-score is currently low at 2.4. The value sub-score of 24.8 reflects the impact of the current P/E multiple on the stock's relative attractiveness. Sentiment remains neutral with a score of 50. Investors should monitor whether the company can maintain its high growth rates to justify these valuation levels throughout the remainder of the fiscal year.
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| D.E. Shaw David Shaw | 11.25M | $1.07B | NEW |
| Citadel Ken Griffin | 6.04M | $575.55M | NEW |
| Marshall Wace | 3.46M | $329.65M | NEW |
| Maverick Capital Lee Ainslie | 2.94M | $280.73M | NEW |
| Point72 Steve Cohen | 2.87M | $273.85M | NEW |
| Renaissance Technologies Jim Simons (founder) | 2.38M | $227.19M | NEW |
| Lone Pine Capital Steve Mandel | 202K | $19.23M | NEW |
| Blackstone | 22K | $2.12M | NEW |
| Politician | Date | Type | Amount |
|---|---|---|---|
| Gilbert Cisneros D-CA | 2026-08-18 | purchase | $1k – $15k |
| Gilbert Cisneros D-CA | 2026-06-05 | purchase | $1k – $15k |
| Gilbert Cisneros D-CA | 2026-05-29 | purchase | $1k – $15k |
| Gilbert Cisneros D-CA | 2026-05-19 | purchase | $1k – $15k |
| Gilbert Cisneros D-CA | 2026-05-11 | purchase | $1k – $15k |
| Gilbert Cisneros D-CA | 2026-01-30 | purchase | $1k – $15k |
| Lisa McClain R-MI | 2025-10-31 | sale | $1k – $15k |
| Lisa McClain R-MI | 2025-10-30 | sale | $1k – $15k |
Boston Scientific Corporation develops, manufactures, and markets a broad portfolio of medical devices designed for minimally invasive procedures worldwide. The company specializes in innovative technologies that address critical health needs across cardiology, endoscopy, and neuromodulation. Its Cardiovascular segment offers products for angioplasty, stents, cardiac rhythm management, and structural heart interventions, while the MedSurg segment provides solutions for endoscopy, urology, neuromodulation for chronic pain, interventional oncology, and treatments for incontinence and kidney stones. These devices enable healthcare professionals to perform precise diagnostics and therapies with reduced patient recovery times. Boston Scientific Corporation serves physicians, hospitals, and healthcare institutions globally, with a significant portion of sales from international markets. Founded in 1979 and headquartered in Marlborough, Massachusetts, it plays a vital role in advancing interventional medicine and improving patient outcomes in high-volume therapeutic areas.
Earnings calendar coming soon. Subscribe to get notified when BSX reports next.
Get earnings alerts →